Cargando…

Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer

BACKGROUND: Molecular targeted therapy including the use of monoclonal antibodies directed against the immune checkpoints PD‐L1 and PD‐1 receptor have remarkably improved the therapeutic response and survival of cancer patients. The tumor expression level of PD‐L1 can predict the response rate to ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Yuki, Kobayashi, Tetsu, Nishii, Yoichi, Suzuki, Yuta, Saiki, Haruko, Ito, Kentaro, Watanabe, Fumiaki, Nishihama, Kota, Yasuma, Taro, D'Alessandro‐Gabazza, Corina N., Katsuta, Koji, Fujimoto, Hajime, Gabazza, Esteban C, Taguchi, Osamu, Hataji, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209791/
https://www.ncbi.nlm.nih.gov/pubmed/30209885
http://dx.doi.org/10.1111/1759-7714.12861
_version_ 1783366970569129984
author Nakamura, Yuki
Kobayashi, Tetsu
Nishii, Yoichi
Suzuki, Yuta
Saiki, Haruko
Ito, Kentaro
Watanabe, Fumiaki
Nishihama, Kota
Yasuma, Taro
D'Alessandro‐Gabazza, Corina N.
Katsuta, Koji
Fujimoto, Hajime
Gabazza, Esteban C
Taguchi, Osamu
Hataji, Osamu
author_facet Nakamura, Yuki
Kobayashi, Tetsu
Nishii, Yoichi
Suzuki, Yuta
Saiki, Haruko
Ito, Kentaro
Watanabe, Fumiaki
Nishihama, Kota
Yasuma, Taro
D'Alessandro‐Gabazza, Corina N.
Katsuta, Koji
Fujimoto, Hajime
Gabazza, Esteban C
Taguchi, Osamu
Hataji, Osamu
author_sort Nakamura, Yuki
collection PubMed
description BACKGROUND: Molecular targeted therapy including the use of monoclonal antibodies directed against the immune checkpoints PD‐L1 and PD‐1 receptor have remarkably improved the therapeutic response and survival of cancer patients. The tumor expression level of PD‐L1 can predict the response rate to checkpoint inhibitors. We evaluated whether the time interval between tumor tissue sampling/paraffinization and immunohistochemistry affects the staining level of PD‐L1 in non‐small cell lung cancer (NSCLC). METHODS: This study comprised 137 patients with NSCLC. Tumors were stained with 22C3 or 28‐8 antibodies. RESULTS: There was a significant correlation between the immunoreactivity rate of tumor tissues obtained using 22C3 and 28‐8 clones. No statistical difference in immunoreactivity between archival and recent samples stained either with 22C3 or 28‐8 antibodies was observed. The immunoreactivity rate achieved with 22C3 or 28‐8 antibodies significantly correlated with tumor histological type and size, but not with specimen storage time, age, gender, smoking history, clinical stage, or lymph node metastasis. CONCLUSION: In brief, the results of this study show that the time interval between tissue sampling/paraffinization and immunohistochemical analysis has no influence on the immunoreactivity rate of PD‐L1 in NSCLC.
format Online
Article
Text
id pubmed-6209791
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-62097912018-11-16 Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer Nakamura, Yuki Kobayashi, Tetsu Nishii, Yoichi Suzuki, Yuta Saiki, Haruko Ito, Kentaro Watanabe, Fumiaki Nishihama, Kota Yasuma, Taro D'Alessandro‐Gabazza, Corina N. Katsuta, Koji Fujimoto, Hajime Gabazza, Esteban C Taguchi, Osamu Hataji, Osamu Thorac Cancer Original Articles BACKGROUND: Molecular targeted therapy including the use of monoclonal antibodies directed against the immune checkpoints PD‐L1 and PD‐1 receptor have remarkably improved the therapeutic response and survival of cancer patients. The tumor expression level of PD‐L1 can predict the response rate to checkpoint inhibitors. We evaluated whether the time interval between tumor tissue sampling/paraffinization and immunohistochemistry affects the staining level of PD‐L1 in non‐small cell lung cancer (NSCLC). METHODS: This study comprised 137 patients with NSCLC. Tumors were stained with 22C3 or 28‐8 antibodies. RESULTS: There was a significant correlation between the immunoreactivity rate of tumor tissues obtained using 22C3 and 28‐8 clones. No statistical difference in immunoreactivity between archival and recent samples stained either with 22C3 or 28‐8 antibodies was observed. The immunoreactivity rate achieved with 22C3 or 28‐8 antibodies significantly correlated with tumor histological type and size, but not with specimen storage time, age, gender, smoking history, clinical stage, or lymph node metastasis. CONCLUSION: In brief, the results of this study show that the time interval between tissue sampling/paraffinization and immunohistochemical analysis has no influence on the immunoreactivity rate of PD‐L1 in NSCLC. John Wiley & Sons Australia, Ltd 2018-09-12 2018-11 /pmc/articles/PMC6209791/ /pubmed/30209885 http://dx.doi.org/10.1111/1759-7714.12861 Text en © 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Nakamura, Yuki
Kobayashi, Tetsu
Nishii, Yoichi
Suzuki, Yuta
Saiki, Haruko
Ito, Kentaro
Watanabe, Fumiaki
Nishihama, Kota
Yasuma, Taro
D'Alessandro‐Gabazza, Corina N.
Katsuta, Koji
Fujimoto, Hajime
Gabazza, Esteban C
Taguchi, Osamu
Hataji, Osamu
Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer
title Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer
title_full Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer
title_fullStr Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer
title_full_unstemmed Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer
title_short Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer
title_sort comparable immunoreactivity rates of pd‐l1 in archival and recent specimens from non‐small cell lung cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209791/
https://www.ncbi.nlm.nih.gov/pubmed/30209885
http://dx.doi.org/10.1111/1759-7714.12861
work_keys_str_mv AT nakamurayuki comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer
AT kobayashitetsu comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer
AT nishiiyoichi comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer
AT suzukiyuta comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer
AT saikiharuko comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer
AT itokentaro comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer
AT watanabefumiaki comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer
AT nishihamakota comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer
AT yasumataro comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer
AT dalessandrogabazzacorinan comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer
AT katsutakoji comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer
AT fujimotohajime comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer
AT gabazzaestebanc comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer
AT taguchiosamu comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer
AT hatajiosamu comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer